Payment overview · 2025
General Payments
$1,134.17
65 reported records · 20 companies
Healthcare provider profile · identity verified
Wayne W Beam, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHILLICOTHE, OH · NPI 1073548921
Verified facts
What the public records show
CMS Open Payments records show Wayne W Beam, MD received $1,134.17 in general payments during 2025 across 65 reported records.
ABBVIE INC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $249.43 | 22.0% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $226.00 | 19.9% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $92.24 | 8.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $76.21 | 6.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.40 | 6.0% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.65 | 4.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.35 | 4.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $45.10 | 4.0% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.95 | 3.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.90 | 3.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.42 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.13 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.82 | 2.1% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $23.69 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.62 | 2.1% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $20.19 | 1.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.66 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.68 | 1.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.20 | 1.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.53 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,089.17 | 64 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $156.11 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $141.20 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $108.23 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.23 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $76.21 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.04 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.04 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.65 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $45.35 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $45.10 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $40.95 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.02 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 139 |
| Lisinopril | Lisinopril | 368 | 96 |
| Losartan Potassium | Losartan Potassium | 348 | 87 |
| Gabapentin | Gabapentin | 342 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 70 |
| Omeprazole | Omeprazole | 292 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 64 |
| Sertraline Hcl | Sertraline Hcl | 242 | 55 |
| Simvastatin | Simvastatin | 242 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 57 |
| Potassium Chloride | Potassium Chloride | 215 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 53 |
| Furosemide | Furosemide | 205 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 42 |
| Metformin Hcl Er | Metformin Hcl | 178 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 40 |
| Montelukast Sodium | Montelukast Sodium | 176 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 29 |
| Clonazepam | Clonazepam | 169 | 27 |
| Lorazepam | Lorazepam | 166 | 33 |
| Carvedilol | Carvedilol | 164 | 44 |
| Mounjaro | Tirzepatide | 155 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 38 |
| Jardiance | Empagliflozin | 147 | 27 |
| Ozempic | Semaglutide | 142 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 34 |
| Famotidine | Famotidine | 139 | 32 |
| Januvia | Sitagliptin Phosphate | 134 | 24 |
| Metformin Hcl | Metformin Hcl | 133 | 36 |
| Memantine Hcl | Memantine Hcl | 131 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 37 |
| Allopurinol | Allopurinol | 124 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 113 | 26 |
| Trazodone Hcl | Trazodone Hcl | 108 | 27 |
| Meloxicam | Meloxicam | 104 | 24 |
| Xarelto | Rivaroxaban | 104 | 12 |
| Tramadol Hcl | Tramadol Hcl | 95 | 21 |
| Eliquis | Apixaban | 93 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 28 |
| Glimepiride | Glimepiride | 81 | 19 |
| Prednisone | Prednisone | 80 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 19 |
| Alendronate Sodium | Alendronate Sodium | 71 | 16 |
| Bupropion Xl | Bupropion Hcl | 70 | 13 |
| Fluconazole | Fluconazole | 68 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Spironolactone | Spironolactone | 64 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 16 |
| Mirtazapine | Mirtazapine | 62 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 13 |
| Azithromycin | Azithromycin | 59 | 49 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 13 |
| Temazepam | Temazepam | 54 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 54 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 22 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 38 |
| Finasteride | Finasteride | 52 | suppressed |
| Alprazolam | Alprazolam | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | 11 |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 12 |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 39 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Primidone | Primidone | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,134.17 · 65 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, Hillrom - Vest System Model 105 Home Care, JARDIANCE, Jornay PM, Kerendia, Korlym, MOUNJARO, NEUROSTAR TMS THERAPY SYSTEM, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REXULTI, TZIELD, UBRELVY, VRAYLAR, WATCHMAN Access System, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error